HU9501411D0 - Pyran-2-one- and 5,6-dihydro-pyran-2-one derivatives for treating hiv- and other retrovirus infections - Google Patents

Pyran-2-one- and 5,6-dihydro-pyran-2-one derivatives for treating hiv- and other retrovirus infections

Info

Publication number
HU9501411D0
HU9501411D0 HU9501411A HU9501411A HU9501411D0 HU 9501411 D0 HU9501411 D0 HU 9501411D0 HU 9501411 A HU9501411 A HU 9501411A HU 9501411 A HU9501411 A HU 9501411A HU 9501411 D0 HU9501411 D0 HU 9501411D0
Authority
HU
Hungary
Prior art keywords
pyran
dihydro
derivatives
treating hiv
retrovirus infections
Prior art date
Application number
HU9501411A
Other languages
English (en)
Other versions
HU228126B1 (en
HUT71558A (en
Inventor
Chih-Ping Yang
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HU9501411D0 publication Critical patent/HU9501411D0/hu
Publication of HUT71558A publication Critical patent/HUT71558A/hu
Publication of HU228126B1 publication Critical patent/HU228126B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU9501411A 1992-11-13 1993-11-09 Pyran-2-one- and 5,6-dihydro-pyran-2-one derivatives useful for treating hiv- and other retrovirus infections HU228126B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US9087693A 1993-07-13 1993-07-13
US13064193A 1993-10-01 1993-10-01
PCT/US1993/010645 WO1994011361A1 (en) 1992-11-13 1993-11-09 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses

Publications (3)

Publication Number Publication Date
HU9501411D0 true HU9501411D0 (en) 1995-06-28
HUT71558A HUT71558A (en) 1995-12-28
HU228126B1 HU228126B1 (en) 2012-12-28

Family

ID=27376682

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9501411A HU228126B1 (en) 1992-11-13 1993-11-09 Pyran-2-one- and 5,6-dihydro-pyran-2-one derivatives useful for treating hiv- and other retrovirus infections

Country Status (26)

Country Link
EP (2) EP0668860B1 (hu)
JP (1) JP3583127B2 (hu)
KR (1) KR100314975B1 (hu)
CN (1) CN1040321C (hu)
AT (2) ATE223910T1 (hu)
AU (1) AU687368B2 (hu)
BR (1) BR9307451A (hu)
CA (1) CA2145661C (hu)
CZ (1) CZ291853B6 (hu)
DE (2) DE69332292T2 (hu)
DK (2) DK0668860T3 (hu)
ES (2) ES2237624T3 (hu)
FI (1) FI120399B (hu)
GE (1) GEP20094660B (hu)
HU (1) HU228126B1 (hu)
IL (1) IL107556A (hu)
LV (1) LV13088B (hu)
MY (1) MY119031A (hu)
NO (1) NO319914B1 (hu)
NZ (1) NZ258013A (hu)
PL (1) PL178653B1 (hu)
PT (2) PT1203770E (hu)
RU (1) RU2134691C1 (hu)
SK (1) SK285001B6 (hu)
WO (1) WO1994011361A1 (hu)
ZA (1) ZA938019B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502713A (ja) * 1993-09-17 1997-03-18 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
ES2191035T3 (es) * 1993-11-19 2003-09-01 Parke Davis & Co Derivados de la pirona como inhibidores de la proteasa y agentes antiviricos.
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
RU2153497C2 (ru) * 1993-11-19 2000-07-27 Парк,Дэвис Энд Компани Производные пирона, фармацевтическая композиция с антивирусной и антибактериальной активностью на их основе и способ лечения вызванных ретровирусом инфекции или заболевания
US5808062A (en) * 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
HUT75225A (en) * 1993-11-19 1997-04-28 Parke Davis & Co 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
JP3684426B2 (ja) * 1993-11-19 2005-08-17 パーク・デイビス・アンド・カンパニー プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
ES2191095T3 (es) * 1995-03-20 2003-09-01 Upjohn Co Acidos tetronicos sustituidos utiles contra el vih y otros retrovirus.
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
HU228986B1 (en) 1997-09-11 2013-07-29 Upjohn Co Process to produce 4-hydroxy-2-oxo-pyrane derivatives useful as protease inhibitors
BR9908706A (pt) 1998-03-12 2000-11-21 Teijin Ltd Derivado de benzofuril-alfa-pirona, composição farmacêutica, acentuador de metabolismo de lipìdeos, inibidor de biossìntese de triglicerìdeos, agente redutor de triglicerìdeos do sangue, agente elevador de hdl do sangue, agente profilático para a arteriosclerose, e, agente de tratamento para a arteriosclerose
EP1281399A3 (en) * 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
EP1680391A1 (de) 2003-10-24 2006-07-19 Lonza Ag Verfahren zur herstellung von 6,6,6-trihalo-3,5-dioxohexans ureestern
CN102336730A (zh) * 2006-06-16 2012-02-01 马尔药品公司 抗肿瘤二羟基吡喃-2-酮化合物
RS52343B (en) 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
WO2010051883A1 (de) 2008-11-05 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
WO2010051893A1 (de) 2008-11-07 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
JP5743219B2 (ja) 2008-11-11 2015-07-01 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド アリル化合物を用いる、モノアリル官能性ジアルキルホスフィン酸、それらの塩およびエステルの製造方法およびそれらの使用
DE102008060036A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
KR101697948B1 (ko) 2008-12-18 2017-01-19 클라리언트 파이넌스 (비브이아이)리미티드 아세틸렌을 사용하는 에틸렌디알킬포스핀산, 에틸렌디알킬포스핀산 에스테르 및 에틸렌디알킬포스핀산 염의 제조방법 및 이의 용도
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
US20120202814A1 (en) * 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN114835694B (zh) * 2022-05-25 2024-06-21 中国科学技术大学 一种在水介质中合成手性3，4-二氢-2h-吡喃类化合物的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope
EP0403535A1 (en) * 1988-03-01 1990-12-27 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans

Also Published As

Publication number Publication date
CN1090279A (zh) 1994-08-03
BR9307451A (pt) 1999-08-31
ATE223910T1 (de) 2002-09-15
LV13088B (en) 2004-01-20
FI952302A (fi) 1995-05-11
IL107556A (en) 2001-08-08
PL178653B1 (pl) 2000-05-31
WO1994011361A1 (en) 1994-05-26
DK1203770T3 (da) 2005-05-23
PT668860E (pt) 2003-01-31
CZ291853B6 (cs) 2003-06-18
NO951899D0 (no) 1995-05-12
DE69333771D1 (de) 2005-04-14
HU228126B1 (en) 2012-12-28
ES2182837T3 (es) 2003-03-16
NO319914B1 (no) 2005-10-03
PL308998A1 (en) 1995-09-18
DE69333771T2 (de) 2006-04-06
GEP20094660B (en) 2009-03-25
DK0668860T3 (da) 2003-01-20
DE69332292T2 (de) 2003-05-28
HUT71558A (en) 1995-12-28
JPH08503216A (ja) 1996-04-09
JP3583127B2 (ja) 2004-10-27
FI952302A0 (fi) 1995-05-11
NO951899L (no) 1995-07-12
KR100314975B1 (ko) 2002-02-28
SK285001B6 (sk) 2006-04-06
NZ258013A (en) 1997-02-24
KR950704290A (ko) 1995-11-17
IL107556A0 (en) 1994-02-27
CA2145661C (en) 2008-04-01
EP0668860B1 (en) 2002-09-11
CA2145661A1 (en) 1994-05-26
DE69332292D1 (de) 2002-10-17
RU95112465A (ru) 1997-03-20
CZ107895A3 (en) 1995-12-13
ES2237624T3 (es) 2005-08-01
ZA938019B (en) 1995-04-28
MY119031A (en) 2005-03-31
RU2134691C1 (ru) 1999-08-20
ATE290531T1 (de) 2005-03-15
EP1203770A1 (en) 2002-05-08
EP1203770B1 (en) 2005-03-09
FI120399B (fi) 2009-10-15
AU687368B2 (en) 1998-02-26
SK61695A3 (en) 1995-10-11
PT1203770E (pt) 2005-05-31
CN1040321C (zh) 1998-10-21
AU5549394A (en) 1994-06-08
EP0668860A1 (en) 1995-08-30

Similar Documents

Publication Publication Date Title
HU9501411D0 (en) Pyran-2-one- and 5,6-dihydro-pyran-2-one derivatives for treating hiv- and other retrovirus infections
LV12316A (lv) 16-aizvietoti 4-azoandrostani ka 5-alfa-reduktazes izozima 1 inhibitori
TW270922B (hu)
GB2344532A (en) Electromagnetic radiation therapy
EP0667769A4 (en) USE OF SPECIFIC ALPHA-1C COMPOUNDS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA.
ZA93811B (en) Methods of treating inflammatory dermatoses.
HUP0000261A3 (en) Means for treating prostate hypertrophy and prostate cancer
ES2105774T3 (es) Procedimiento de tratamiento de la alopecia androgena con inhibidores de la 5-alfa reductasa.
EP0748221A4 (en) 7-SUBSTITUTED-4-AZA-STEROID DERIVATIVES AS 5-ALPHA REDUCTASE INHIBITORS
EP0756481A4 (en) 17 BETA ARYL 4 AZA STEROID DERIVATIVES
HU9501286D0 (en) Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
EP0633781A4 (en) COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY.
AU5819996A (en) Topically applicable agents for treating and preventing alopecia
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
IL135516A0 (en) Process for n-desmethylating erythromycins and derivatives thereof
AU6172896A (en) Melatonin agonists for treating benign prostatic hyperplasia
ZA978162B (en) Means for treating prostate hypertrophy and prostate cancer.
AU6083494A (en) Combination method for treating patterned alopecia with 17beta -n-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3- ones and minoxidil
ZA922010B (en) Improved method of treatment for benign prostatic hyperplasia
AU6374798A (en) Methods and compositions of (+) doxazosin for the treatment of hypertension and benign prostatic hyperplasia
EP0654997A4 (en) COMPOSITIONS OF SUBSTITUTED AZASPIRANS AND METHOD FOR TREATING PSORIASIS THEREFOR.
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.